Cytokine Based Immunotherapy for Cancer and Lymphoma: Biology, Challenges and Future Perspectives

被引:37
|
作者
Atallah-Yunes, Suheil Albert [1 ]
Robertson, Michael J. [1 ]
机构
[1] Indiana Univ Sch Med, Dept Hematol & Med Oncol, Indianapolis, IN 46202 USA
来源
FRONTIERS IN IMMUNOLOGY | 2022年 / 13卷
关键词
cytokines; immunotherapy; interleukins; cancer; lymphoma; RECOMBINANT HUMAN INTERLEUKIN-12; NON-HODGKINS-LYMPHOMA; NATURAL-KILLER-CELLS; ALPHA-2 INTERFERON THERAPY; IN-VIVO; PHASE-I; DOSE-ESCALATION; NK CELLS; COMBINATION; RITUXIMAB;
D O I
10.3389/fimmu.2022.872010
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Cytokines regulate both the innate and adaptive immune responses to cancer. Although antitumor activity has been seen for several cytokines in preclinical models, they have had limited success as single therapeutic agents in clinical trials of cancer immunotherapy. However, the possible combinations of cytokines with other immune therapeutics and the advancement in genetic engineering, synthetic biology and cellular and immune therapy has led to the revival of interest in cytokines as anticancer agents. This article will review several immunostimulatory cytokines with anticancer activity, focusing on the those that have been studied in treatment of lymphoma and highlighting recent advances of potential clinical relevance.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Cancer Immunotherapy: Current and Future Perspectives on a Therapeutic Revolution
    Rizzo, Alessandro
    Mollica, Veronica
    Santoni, Matteo
    Massari, Francesco
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (22)
  • [42] Current evidence and future perspectives on immunotherapy for cervical cancer
    Hasegawa, Kosei
    ANNALS OF ONCOLOGY, 2021, 32 : S259 - S259
  • [43] Hepatotoxicity in Cancer Immunotherapy: Diagnosis, Management, and Future Perspectives
    Savino, Alberto
    Rossi, Alberto
    Fagiuoli, Stefano
    Invernizzi, Pietro
    Gerussi, Alessio
    Vigano, Mauro
    CANCERS, 2025, 17 (01)
  • [44] Resveratrol for cancer therapy: Challenges and future perspectives
    Ren, Boxu
    Kwah, Marabeth Xin-Yi
    Liu, Cuiliu
    Ma, Zhaowu
    Shanmugam, Muthu K.
    Ding, Lingwen
    Xiang, Xiaoqiang
    Ho, Paul Chi-Lui
    Wang, Lingzhi
    Ong, Pei Shi
    Goh, Boon Cher
    CANCER LETTERS, 2021, 515 : 63 - 72
  • [45] Current standards and future directions in immunotherapy: perspectives on challenges and opportunities for the allergist
    Bernstein, David I.
    Blaiss, Michael S.
    Cox, Linda S.
    Finegold, Ira
    Lanier, Bobby Q.
    Nelson, Harold S.
    Wallace, Dana V.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2011, 107 (05) : 422 - 425
  • [46] Immunotherapy for prostate cancer: recent developments and future challenges
    Michael T. Schweizer
    Charles G. Drake
    Cancer and Metastasis Reviews, 2014, 33 : 641 - 655
  • [47] Combination immunotherapy for pancreatic cancer: challenges and future considerations
    Gossling, Gustavo C. L.
    Zhen, David B.
    Pillarisetty, Venu G.
    Chiorean, E. Gabriela
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2022, 18 (11) : 1173 - 1186
  • [48] Immunotherapy of gastric cancer: Past, future perspective and challenges
    Xie, Jun
    Fu, Liping
    Jin, Li
    PATHOLOGY RESEARCH AND PRACTICE, 2021, 218
  • [49] Immunotherapy for prostate cancer: recent developments and future challenges
    Schweizer, Michael T.
    Drake, Charles G.
    CANCER AND METASTASIS REVIEWS, 2014, 33 (2-3) : 641 - 655
  • [50] Soypeptide lunasin in cytokine immunotherapy for lymphoma
    Chang, Hua-Chen
    Lewis, David
    Tung, Chun-Yu
    Han, Ling
    Henriquez, Sarah M. P.
    Voiles, Larry
    Lupov, Ivan P.
    Pelloso, David
    Sinn, Anthony L.
    Pollok, Karen E.
    de Lumen, Ben O.
    Li, Fang
    Blum, Janice S.
    Srivastava, Shivani
    Robertson, Michael J.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2014, 63 (03) : 283 - 295